Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, highlights several potential strategies to address the historic lack of diversity in multiple myeloma clinical trial populations.
Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, highlights several potential strategies to address the historic lack of diversity in multiple myeloma (MM) clinical trial populations.
Transcript
What efforts are being made to ensure diversity and representation of underrepresented groups in clinical trials for MM studies?
This is a great disparity in multiple myeloma where now, in the United States, we estimate that approximately 20% of all patients with myeloma are of African American descent, like myself. And yet, representation in clinical trials has historically been somewhere between 5% to 8%, and arguably even less in pivotal trials that have led to drug approval.
This is a grave problem, because it's not only a lack of representation in those trials, it's a lack of understanding of the efficacy and toxicity of these agents in all different patients. We're already starting to see in immunotherapies, there can be differences in the rates of cytokine release syndrome and neurological toxicities in patients of African descent and in Hispanic American patients, for example.
So this is a huge problem, and I think there isn't going to be a simple and rapid solution, but many solutions are being proposed that include addressing the hierarchical system of systemic racism, of access to health care, of trust within the system—but also very pragmatic answers of ensuring that clinical trials have a diversity officer, that the materials are designed to be able to be read by and supported by a diverse population that we, as health care providers, are trained in understanding culturally sensitive care, so that we can not be a barrier but be a facilitator of the best care of our patients, which very often includes clinical trials.
These are just some of the highlighted issues that I think will help solve the problem as we tried to develop a system that has much greater community engagement. I think that has been a missing piece in our health care systems: that we've been so focused on explicit health care that we haven't looked at the greater interest of engaging our communities at large, which will build that trust [and] which will build that confidence to be able to work together more.
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen